Thurston Springer Miller Herd & Titak’s Moderna MRNA Stock Holding History

Thurston Springer Miller Herd & Titak’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.2K	Hold	145	–	–	﹤0.01%	841
2026 Q1	$7.37K	Hold	145	–	–	﹤0.01%	970
2025 Q4	$4.28K	Buy	145 +45	+45%	+$1.22K	﹤0.01%	1122
2025 Q3	$2.58K	Sell	100 -69	-41%	-$1.93K	0.01%	461
2025 Q2	$4.66K	Buy	169 +58	+52%	+$1.53K	﹤0.01%	1300
2025 Q1	$3.15K	Hold	111	–	–	﹤0.01%	1368
2024 Q4	$4.62K	Hold	111	–	–	﹤0.01%	1030
2024 Q3	$7.42K	Hold	111	–	–	﹤0.01%	1121
2024 Q2	$13.2K	Buy	+111	New	+$14K	﹤0.01%	923

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Thurston Springer Miller Herd & Titak's MRNA Position: Q2 2026 in Review

Thurston Springer Miller Herd & Titak held its Moderna (MRNA) position steady in Q2 2026 at 145 shares worth $10.2K. The position accounts for ﹤0.01% of the portfolio, ranked #841.

Thurston Springer Miller Herd & Titak first reported a position in MRNA in Q2 2024 and has held it in 9 quarters since. The position peaked at $13.2K in Q2 2024. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

Thurston Springer Miller Herd & Titak held 145 shares of Moderna worth $10.2K as of Q2 2026.
Thurston Springer Miller Herd & Titak left its Moderna share count unchanged in Q2 2026.
Moderna made up ﹤0.01% of Thurston Springer Miller Herd & Titak's portfolio in Q2 2026, its #841 holding.
Thurston Springer Miller Herd & Titak first reported a position in Moderna in Q2 2024 and has held it in 9 quarters since.
Thurston Springer Miller Herd & Titak's Moderna position peaked at $13.2K in Q2 2024.
782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Thurston Springer Miller Herd & Titak's 13F filing for Q2 2026, filed 8 Jul 2026.